StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Epkinly (epcoritamab) — U.S. net revenues by Quarter

Epkinly (epcoritamab) — U.S. net revenues ($M) ($M)

QuarterlyAnnual

AbbVie Epkinly (epcoritamab) — U.S. net revenues: $64M in Q2 2026, up 30.6% from a year earlier. That is the highest of the 16 quarters on record here.

Latest, Q2 2026
64
Period ended Jun 30, 2026
Change on a year earlier
+30.6%
49 in Q2 2025
History
16 quarters
Since Q3 2022
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-03) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEpkinly (epcoritamab) — U.S. net revenues ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202664+30.6%Form 10-Q (filed 2026-08-03) ↗
Q1 2026Mar 31, 202651+41.7%Form 10-Q (filed 2026-05-08) ↗
Q4 2025Dec 31, 202552+44.4%Form 10-K (filed 2026-02-20) ↗
Q3 2025Sep 30, 202544+41.9%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 30, 202549+69.0%Form 10-Q (filed 2026-08-03) ↗
Q1 2025Mar 31, 202536+63.6%Form 10-Q (filed 2026-05-08) ↗
Q4 2024Dec 31, 202436+157.1%Form 10-K (filed 2026-02-20) ↗
Q3 2024Sep 30, 202431+121.4%Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 202429–Form 10-Q (filed 2025-08-04) ↗
Q1 2024Mar 31, 202422–Form 10-Q (filed 2025-05-09) ↗
Q4 2023Dec 31, 202314–Form 10-K (filed 2026-02-20) ↗
Q3 2023Sep 30, 202314–Form 10-Q (filed 2024-11-04) ↗
Q2 2023Jun 30, 20230–Form 10-Q (filed 2024-08-07) ↗
Q1 2023Mar 31, 20230–Form 10-Q (filed 2024-05-03) ↗
Q4 2022Dec 31, 20220–Form 10-K (filed 2025-02-14) ↗
Q3 2022Sep 30, 20220–Form 10-Q (filed 2023-11-06) ↗

Breakdown

What makes up epkinly (epcoritamab) — U.S. net revenues

Cite this data

StockData. (2026). AbbVie Epkinly (epcoritamab) — U.S. net revenues ($M), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/epkinly-us

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.